JP2017218380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017218380A5 JP2017218380A5 JP2016111280A JP2016111280A JP2017218380A5 JP 2017218380 A5 JP2017218380 A5 JP 2017218380A5 JP 2016111280 A JP2016111280 A JP 2016111280A JP 2016111280 A JP2016111280 A JP 2016111280A JP 2017218380 A5 JP2017218380 A5 JP 2017218380A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- irradiation
- subcutaneous tumor
- nicaraben
- physiological saline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000035492 administration Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drugs Drugs 0.000 description 3
- KTXBOOWDLPUROC-UHFFFAOYSA-N N-[2-(pyridine-3-carbonylamino)propyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C)CNC(=O)C1=CC=CN=C1 KTXBOOWDLPUROC-UHFFFAOYSA-N 0.000 description 2
- 229950009737 Nicaraven Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016111280A JP6682116B2 (ja) | 2016-06-02 | 2016-06-02 | ガン転移抑制剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016111280A JP6682116B2 (ja) | 2016-06-02 | 2016-06-02 | ガン転移抑制剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017218380A JP2017218380A (ja) | 2017-12-14 |
| JP2017218380A5 true JP2017218380A5 (de) | 2018-09-13 |
| JP6682116B2 JP6682116B2 (ja) | 2020-04-15 |
Family
ID=60658359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016111280A Active JP6682116B2 (ja) | 2016-06-02 | 2016-06-02 | ガン転移抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6682116B2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024024923A1 (ja) * | 2022-07-28 | 2024-02-01 | 株式会社サイエンステクノロジーインタラクト | がんを治療するための医薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3170364B2 (ja) * | 1992-11-05 | 2001-05-28 | 中外製薬株式会社 | 放射線障害防護剤 |
| JP2004277315A (ja) * | 2003-03-14 | 2004-10-07 | Mitsubishi Pharma Corp | 抗腫瘍剤 |
| JP2005029573A (ja) * | 2003-06-18 | 2005-02-03 | Mitsubishi Pharma Corp | 腫瘍転移抑制剤 |
| ATE521341T1 (de) * | 2003-12-01 | 2011-09-15 | Kudos Pharm Ltd | Dna-schäden-reparatur-hemmer zur behandlung von krebs |
| JP2007056004A (ja) * | 2005-07-26 | 2007-03-08 | Kissei Pharmaceut Co Ltd | 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
-
2016
- 2016-06-02 JP JP2016111280A patent/JP6682116B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017516775A (ja) | がんの処置のための併用治療 | |
| JP2016528162A5 (de) | ||
| JP2010531877A5 (de) | ||
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2016508987A5 (de) | ||
| JP2019512495A5 (de) | ||
| JP2009536956A5 (de) | ||
| JP2016526531A5 (de) | ||
| JP2017218380A5 (de) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2016510040A5 (de) | ||
| WO2011149250A2 (ko) | 트리카르보닐 테크네슘-99ｍ 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 | |
| Stamets | Trametes versicolor (Turkey Tail Mushrooms) and the treatment of breast cancer | |
| Voulgari et al. | Transfusion-related acute lung injury during intravenous immunoglobulin treatment | |
| JP2018199726A5 (de) | ||
| WO2014050912A1 (ja) | 二酸化炭素を溶解した液状医薬とそれを用いる治療方法 | |
| CN103520161A (zh) | 左西孟旦作为制备酰胺类局麻药中毒所致心脏停搏后心肺复苏药的应用及心肺复苏治疗方法 | |
| Evstigneev et al. | Photodynamic therapy and diagnosis of lower lip cancer with photosense | |
| KR20210022577A (ko) | 종양 진행 제어용 또는 항 종양 면역 회복용 대식 세포 및 조사된 백혈구의 공동 배양으로부터의 상청액 | |
| Shojaku | Various toxicities in an elderly patient following intra-arterial administration: case report | |
| RU2554750C1 (ru) | Способ лечения рака легкого | |
| Kotopoulis et al. | Ultrasound sonoporation in pancreatic adenocarcinoma | |
| RU2021107897A (ru) | Лекарственное средство для облегчения состояний и/или подавления возникновения периферической невропатии, вызванной агентом против злокачественной опухоли | |
| US20190290657A1 (en) | Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy | |
| Mauseth et al. | LTX-401 as a novel antitumor and immunotherapeutic agent in an experimental liver cancer model |